Cipla surges 8% after completing a Phase-3 clinical study of asthma drug
Published On: Friday, April 3, 2020 | By: Team KnowMyStock
One of the leading pharma companies Shares of Cipla surged 8 per cent in a weak market, to Rs 447.2 on Friday after the pharmaceutical firm completed Phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder used to treat asthma patients. The stock has gained 19 per cent in the last week after hitting a six-year low following the selloff triggered by the coronavirus outbreak. Fluticasone propionate and salmeterol inhalation powder 100/50 mcg, 250/50 mcg and 500/50 mcg are generic versions of GSK's Advair Diskus. It is used in giving medical treatment to asthma patients 4 years and older. It is also used in the long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flareups. The Phase-3 study was conducted over a period of 15 months, at over 100 sites in the US enrolling 1400 asthma patients.
Cipla will now file the product with the USFDA which will take 3 to 4 months for approval. Being a complex product and based on past experience with other players (Mylan, Hikma, Sandoz), it is highly likely that the approval pathway will be longer than the usual one-year cycle," analysts at Emkay Global said in a recent report.
We are on Telegram!
JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.
Click Here!
Follow Us On:
